| Trial ID: | L0650 |
| Source ID: | JPRN-UMIN000009133
|
| Associated Drug: |
Levocarnitine
|
| Title: |
|
| Acronym: |
--
|
| Status: |
Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Non-Alcoholic Fatty Liver Disease (NAFLD)
|
| Interventions: |
Levocarnitine at a 600mg thrice daily for 6months<br>control
|
| Outcome Measures: |
Improvement of serum ALT after taking Levocarnitine for 6 monthsThe following items are assessed after taking Levocarnitine for 6 months<br>1. Safety<br>2. Improvement of metabolic disorder<br>3. Improvement of histological findings of the liver<br>4. the effect of Levocarnitine on the gene expression(mRNA)<br>5. The effect of Levocarnitine on immunoreaction in the liver<br>6. The concentration of the Levocarnitine and the effect of Levocarnitine on fatty acid composition in the liver
|
| Sponsor/Collaborators: |
Kanazawa University Graduate School of Medical Science, Disease Contral and Homeostasis
|
| Gender: |
All
|
| Age: |
20years-old80years-old
|
| Phases: |
Not selected
|
| Enrollment: |
80
|
| Study Type: |
Interventional
|
| Study Designs: |
Parallel Randomized
|
| Start Date: |
17/10/2012
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
2 April 2019
|
| Locations: |
Japan
|
| URL: |
https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010696
|
